

## Emergency contact information:

Emergency Prescriber Contact:	
Telephone number during office hours:	
Telephone number after office hours:	

Further information is available in the patient brochure.



Date of preparation of text: November 2022  
NP-UK--0041  
Version 1.0

Approved by MHRA: November 2022

## Information for Patients and Healthcare Professionals

**Lenalidomide is structurally related to thalidomide and is expected to cause severe birth defects or death to an unborn baby therefore:**

- Female patients of childbearing potential must always use effective contraception
- Female patients of childbearing potential must have pregnancy tests every 4 weeks, prior to each prescription, to ensure that they are not pregnant, except in the case of confirmed tubal sterilisation
- Male patients with pregnant partners or partners of childbearing potential not using effective contraception must always use condoms (even if man has had a vasectomy)
- If a female patient or female partner of a male patient suspects they are pregnant, they must contact their prescriber immediately
- You MUST tell your prescriber immediately if you experience any symptom that causes concern

**For complete information on the side effects of lenalidomide, patients should read the Package Leaflet and HCPs should read the Summary of Product Characteristics.**

## Information for Healthcare Professionals:

### Prescription Details

Has the patient received counselling?	YES	NO	
Childbearing potential assessment:	WCBP	WNCBP	MALE
If the patient is a WCBP is she using effective contraception?	YES	NO	
If the patient is male, is he using condoms, if required?	YES	NO	

**A completed Prescription Authorisation Form must accompany each prescription to confirm that the patient continues to use effective contraception (if required) and, in the case of a WCBP, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant.**

## Information for Healthcare Professionals:

### Prescription Details

This patient is receiving lenalidomide for treatment of:

- Multiple Myeloma **OR**
- Myelodysplastic Syndromes **OR**
- Mantle Cell Lymphoma **OR**
- Follicular Lymphoma